X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


Latest Post

May 22, 2020

SARS-CoV-2 Vaccines – Primary Packaging Challenges

Developing a SARS-CoV-2 vaccine presents numerous and unprecedented challenges; prominent among them are greatly accelerated timelines. Ordinarily for a new drug product, there is sufficient time for selection/evaluation of the vial/stopper packaging system – one that guarantees quality and safety from manufacture through delivery. This is not the case for a SARS-CoV-2 vaccine where the primary packaging system must be chosen quickly, creating a higher risk.
Page McAndrew

Page McAndrew PhD.

Director, Scientific Communications

Categories

Search the Blog

Archive

{1}

{2}
{3}

{4}

  • Previous Posts
    AFM topography and modulus mapping image

    April 10, 2020

    Not All Barriers Are Created Equal

    Cathy Zhao

    Cathy Zhao

    Director, Scientific Insights Lab

    Fluoropolymer

    December 06, 2019

    Advantages of Fluoropolymer-Laminated Components

    Candice Sun

    Candice Sun

    Specialist, Scientific Affairs, CN

    B2 Coating Stoppers

    March 04, 2019

    The Smart Solution When Silicone Oil is an Issue

    Simon Meurer

    Simon Meurer

    Manager, TCS, Commercial

    FluroTec Barrier Film Coating

    January 29, 2019

    Effective Drug Protection for Plungers in a Prefillable Syringe System

    Christa Jansen-Otten

    Christa Jansen-Otten

    Director, Product Mgmt, PFS & Delivery

    Load more